SemBioSys Genetics Inc. is a biotechnology company developing insulin and other protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company’s lead candidate, produced in the plant host safflower, are recombinant human insulin (insulin) to serve the global diabetes market, and apolipoprotein AI and apolipoprotein AI Milano (collectively referred to as Apo AI), a potential next-generation cardiovascular drug. In addition to its pharmaceutical products, the Company is developing a series of non-pharmaceutical products addressing the agricultural biotechnology and nutritional oils markets. Its wholly owned subsidiary, Botaneco Specialty Ingredients Inc., is focused on the commercialization of its first branded line of non-transgenic, oilbody-based ingredients, marketed under the trade name Hydresia, and the development of additional future lines of cosmetic, personal care and prescription topical/dermatology ingredients, which are in the development stage.
(Source: ARS) – less–ZoomInfo